Tumour necrosis factor-alpha potentiates CR3-induced respiratory burst by activating p38 MAP kinase in human neutrophils.
CR3 and Fc gamma Rs are the main receptors involved in the phagocytic process leading to engulfment and killing of microbes by production of reactive oxygen intermediates (ROI) and degranulation. Various inflammatory mediators, such as tumour necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS), are known to prime neutrophils leading to increased bactericidal responses, but the underlying mechanism of priming has only been partially elucidated. The purpose of this study was to investigate how TNF-alpha primes neutrophils for subsequent stimuli via either CR3 or Fc gamma R. The receptors were specifically activated with pansorbins (protein-A-positive Staphylococcus aureus) coated with anti-CR3, anti-Fc gamma RIIa, or anti-Fc gamma RIIIb monoclonal antibody. Activation of neutrophils with these particles resulted in ROI production as measured by chemiluminescence. Anti-CR3 pansorbins induced the most prominent ROI production in neutrophils. TNF-alpha potentiated the CR3-mediated respiratory burst but had little effect on that mediated by Fc gamma Rs. The priming effect of TNF-alpha on CR3-mediated ROI production is associated with an increased activation of p38 MAPK as well as tyrosine phosphorylation of p72(syk). Pretreatment of neutrophils with the inhibitors for p38 MAPK and p72(syk) markedly suppressed the respiratory burst induced by CR3. Furthermore, TNF-alpha induced about a three-fold increase in the expression of CR3 in neutrophils, an effect which is blocked by the p38 MAPK inhibitor. Taken together, these results showed that TNF-alpha potentiates the CR3-mediated respiratory burst in neutrophils not only by triggering a p38 MAPK-dependent up-regulation of CD11b/CD18 but also by modulating the signalling pathways.
Forsberg
M
M
Division of Medical Microbiology, Department of Health and Care, Faculty of Health Sciences, Linköping University, SE-581 85 Linköping, Sweden. mariakristina@IHM.LiU.se
Löfgren
R
R
Zheng
L
L
Stendahl
O
O
D018821:CD18 Antigens / Q000378:metabolism; D018929:Cell Culture Techniques; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D016177:Macrophage-1 Antigen / Q000276:immunology* / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D018375:Neutrophil Activation / Q000276:immunology; D009504:Neutrophils / Q000201:enzymology* / Q000276:immunology; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D017452:Receptors, IgG / Q000276:immunology; D016897:Respiratory Burst / Q000276:immunology*; D013205:Staphylococcal Protein A / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*; D048051:p38 Mitogen-Activated Protein Kinases
D018821:CD18 Antigens; D004791:Enzyme Inhibitors; D007093:Imidazoles; D016177:Macrophage-1 Antigen; D011725:Pyridines; D017382:Reactive Oxygen Species; D017452:Receptors, IgG; D013205:Staphylococcal Protein A; D014409:Tumor Necrosis Factor-alpha; D011505:Protein-Tyrosine Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580